Biomarin Pharmaceutical Inc to Discuss Results from the Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A Presented at the WFH Virtual Summit Transcript
Good afternoon and good evening, and thank you for joining us to discuss the late-breaker update on ROCTAVIAN gene therapy for hemophilia A as presented today at the World Federation of Hemophilia Virtual Summit by Professor John Pasi.
Today's press release is available on the Investor page of our website as well as the slides being presented during this call. In keeping with the format of the World Federation of Hemophilia meeting, we are using Zoom conferencing technology today, so all participants, with the exception of the speakers, have been muted. Thank you for submitting your questions in advance of this call and for your patience as we embrace this new technology.
Our host today is Dr. Hank Fuchs, BioMarin's President Worldwide Research and Development, who will introduce our guest speakers momentarily. To remind you, this nonconfidential presentation contains forward-looking statements about the development of BioMarin's the valoctocogene roxaparvovec program generally and the impact of the valoctocogene roxaparvovec gene
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
